Report #2831776

Received Mar 17, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: 85 yrs
State: NY
Recovered: Unknown
Vaccinated: Dec 30, 2024
Onset: Dec 30, 2024
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	—	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

internal between 1st dose and 2nd dose was too long; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 85-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (recived 1st dose on 04-DEC-2021). On 30-DEC-2024, the patient received the 2nd dose of Shingrix. On 30-DEC-2024, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: internal between 1st dose and 2nd dose was too long). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK receipt date: 10-MAR-2025 The patient received 2nd dose of Shingrix, later than the recommended interval, which led to lengthening of vaccination schedule.